Entrar Registro gratuito

Last updated: 16 May 2024 at 4:06pm EST

Aleksandra Rizo Net Worth



Aleksandra Rizo biography

Aleksandra Rizo M.D. Ph.D. serves as Executive Vice President, Chief Medical Officer of the Company. Prior to joining Geron, Dr. Rizo was Executive Director, Strategy and Clinical Lead at Celgene Corporation, a biopharmaceutical company, from March 2018 to January 2019, where she led submission activities and participated in strategic and business development initiatives. From October 2008 to March 2018, Dr. Rizo served in a number of oncology drug development functions at Janssen Research and Development, LLC, a pharmaceutical company, including Senior Director, Compound Development Team Leader for all Phase 1 myeloid assets, and Global Clinical Leader for all late-stage myeloid assets, including imetelstat from November 2014 to March 2018, as well as Global Clinical Leader for the ibrutinib mantle cell lymphoma program. In these roles, she had oversight and leadership responsibilities for overall clinical development strategy, study designs, execution and data interpretation. In addition, Dr. Rizo was a core member of Janssen’s Hematology Strategy Team where she participated and led diligence projects in hematology. During her initial tenure with Janssen, Dr. Rizo also worked on a variety of Velcade clinical trials in lymphoma and multiple myeloma. Dr. Rizo holds an M.D. from the University Ss Cyril and Methodius, Skopje, Macedonia, where she also completed a residency in internal medicine/hematology. She also has a Ph.D. in human leukemic stem cell biology from the University of Groningen, Groningen, Netherlands, and a Ph.D. in mouse stem cell biology from the University of Tokyo, Tokyo, Japan.

What is the salary of Aleksandra Rizo?

As the Executive Vice President e Chief Medical Officer of Geron, the total compensation of Aleksandra Rizo at Geron is $1,531,450. There are 1 executives at Geron getting paid more, with John Scarlett having the highest compensation of $1,941,140.



How old is Aleksandra Rizo?

Aleksandra Rizo is 45, she's been the Executive Vice President e Chief Medical Officer of Geron since 2019. There are 20 older and no younger executives at Geron. The oldest executive at Geron Corp. is Stephen N. Rosenfield, 71, who is the Exec. VP, Chief Legal Officer & Corp. Sec..

What's Aleksandra Rizo's mailing address?

Aleksandra's mailing address filed with the SEC is 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, , WALTHAM, MA, 02451.

Insiders trading at Geron

Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury, eStephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.



What does Geron do?

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.



What does Geron's logo look like?

Geron Corp. logo

Geron executives and stock owners

Geron executives and other stock owners filed with the SEC include: